PFE vs SAVA

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...

Cassava Sciences continues to face an existential crisis due to unresolved allegations of data manipulation and ongoing regulatory investigations by the FDA and NIH concerning its lead drug candidate, simufilam. While the Alzheimer's market offers theoretical 10x growth potential, this is fundamentally undermined by a profound trust deficit in leadership and the scientific integrity of their core ...